Joseph Mehltretter, MSc

Articles by Joseph Mehltretter, MSc

Value-Based Care Interventions and Management of CKD Progression

ByMelissa Feeney, PhD,Joseph Mehltretter, MSc,Tammy Cheung, MSc,Emily Simon, BS,Farhad Modarai, DO

October 8th 2025

Patients with chronic kidney disease (CKD) stages 3b or 4 experienced slower decline in estimated glomerular filtration rate 20 months after enrollment in a value-based kidney care program.

Latest Updated Articles

Value-Based Care Interventions and Management of CKD Progression
October 8th 2025

Joseph Mehltretter, MSc

Articles by Joseph Mehltretter, MSc

Value-Based Care Interventions and Management of CKD Progression

Latest Updated Articles

Trending on AJMC

Tavapadon for Parkinson Disease Approved by FDA

Baricitinib Approved for Severe Alopecia Areata in Adolescents

Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices

Access and Innovation in North Carolina’s Research Triangle

DME Drug Remigromig Hits Primary End Point in Phase 3 Trial

Building a Cellular Therapy Program in the Community Oncology Setting: Perspectives and Lessons Learned

Joseph Mehltretter, MSc

Articles by Joseph Mehltretter, MSc

Value-Based Care Interventions and Management of CKD Progression

Latest Updated Articles

Trending on AJMC

Tavapadon for Parkinson Disease Approved by FDA

Baricitinib Approved for Severe Alopecia Areata in Adolescents

Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices

Access and Innovation in North Carolina’s Research Triangle

DME Drug Remigromig Hits Primary End Point in Phase 3 Trial